Session 8 - Treatment and pathophysiology of allergic diseases and COVID-19

October 13, 2022
7:30-9:30 am US Central
2:30-4:30 pm Central Europe

Moderator
Thomas Bieber, MD PhD MDRA

Intro & Welcome

7:30-7:45 am
Three-year follow up of biological therapy for severe asthma in Japan
Shin Ohta, MD PhD
Abstract #70

7:45-8:00 am
A mechanism how leptin is involved in the pathogenesis of asthma
Ken Ohta, MD, PhD FAAAAI
Abstract #71

8:00-8:15 am
Efficacy of an anti-IL-4/IL-13 vaccine in models of chronic allergic asthma in mice
Laurent Reber, PhD
Abstract #72

8:15-8:30 am
Lung neutrophil targeting impairs the subsequent development of house dust mite-induced allergic airway inflammation
Thomas Marichal, DVM, PhD
Abstract #73

8:30-8:45 am
Cysteinyl-maresin 3 inhibits IL-13 induced airway hyperreactivity through alternative activation of the CysLT1 receptor
Jesper Säfholm
Abstract #74

8:45-9:00 am
Fractional Exhaled Nitric Oxide Levels and Efficacy Outcomes in Patients With Uncontrolled, Moderate-to-Severe Asthma Treated With Dupilumab: Results From the Phase 3 LIBERTY ASTHMA QUEST Study
Yamo Deniz, MD, FAAAAI
Abstract #75

9:00-9:15 am
Maternal and cord blood immune cell composition and function at delivery are altered by SARS-CoV-2 infection in pregnancy
Jessica A. Breznik, PhD
Abstract #76

9:15-9:30 am
Mannose decorated exosomes with RNA nanoparticles harboring miR-511-3p protects against allergic asthma
Peisong Gao, MD PhD
Abstract #77

Closing Remarks
Thomas Bieber, MD PhD MDRA

© 2023 Collegium Internationale Allergologicum. All rights reserved.
Privacy Notice | Website Terms of Use